3,5,7-Trihydroxy-2-[3-(3-hydroxy-4-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one

• 分子结构分类: 有机化合物 - 木脂素、新木脂素和相关化合物 - 黄酮木脂素
• 英文名称: 3,5,7-Trihydroxy-2-[3-(3-hydroxy-4-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one
• 化学式: C₂₅H₂₂O₁₀
• 分子量: 482.4
• InChiKey: KDMGQPNVTKUNHV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  35
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  155
• 氢给体数：
  5
• 氢受体数：
  10

文献信息

• SILIBININ COMPONENT FOR THE TREATMENT OF HEPATITIS
  申请人：Madaus GmbH

  公开号：EP2219642A1

  公开（公告）日：2010-08-25
• Silibinin component for the treatment of hepatitis
  申请人：Madaus GmbH

  公开号：EP2392326B1

  公开（公告）日：2018-01-24
• A method for preparing AMORPHOUS SILIBININ
  申请人：Madaus GmbH

  公开号：EP2430017B1

  公开（公告）日：2016-06-29
• AMORPHOUS SILIBININ FOR THE TREATMENT OF VIRAL HEPATITIS
  申请人：Rovati Lucio Claudio

  公开号：US20120108825A1

  公开（公告）日：2012-05-03

  The invention relates to a method for the preparation of amorphous silibinin (or its synonyms: silybin or silibin) derived from a milk thistle fruit extract having an increased release rate and improved absorbability or bioavailability, and to the use of amorphous silibinin for the treatment or prevention of liver diseases, preferably for the treatment of viral hepatitis, e.g. hepatitis B or C, in particular in a patient who will undergo or has undergone liver transplantation. Preferably, the amorphous silibinin is adapted for oral administration.
• US8614341B2
  申请人：——

  公开号：US8614341B2

  公开（公告）日：2013-12-24